Intriguingly, HER3 phosphorylation has been repeatedly observed as a bypass mechanism of resistance to BRAF and MEK1/2 inhibitors in melanoma, indicating that there may be additional mechanisms in which HER3 plays a critical and central role in acquired resistance [65–68]. Here, ERBB3 is linked to melanoma.